



March 10, 2008

Licensing Assistance Team  
Division of Nuclear Materials Safety  
U.S. Nuclear Regulatory Commission, Region 1  
475 Allendale Road  
King of Prussia, PA 19406-1415

MS16  
K-8

RE: Byproduct Material License Amendment Request  
City Hospital, Inc.  
NRC License No. 47-15501-01  
Docket No. 03009218  
Mail Control No: 141722

Dear License Reviewers:

Enclosed please find the response to Sandra Gabriel email dated Sunday, February 24, 2008.

- Items 1-3 no response needed
- Item 4: Arrangements have been established for brachytherapy training for Dr. Misailidis, Radiation Safety Officer City Hospital, Inc. WVUH-East, with Dr. Nasser Razmianfar, Director and Radiation Safety Office for West Virginia University Hospital.
- Items 5 & 6: A thin crystal meter, tongs and glass vial for water and placement of dislodges source seeds has been ordered for seed preparation and surgery.
- Item 7: Enclosed please find a letter from Katin Radiation Therapy addressing release provisions of 10 CFR 35.75.
- Item 9: Please find enclosed a copy of the written directive provided by Katin Radiation Therapy.

If there are any questions or additional information is needed, please contact me at 304-264-1350 or our Health Physics Consultant, Ms. Michele Losocco of Krueger-Gilbert Health Physics, Inc. at 410-665-5447.

Sincerely,

*Brenda Wonsetler, RT(R)*

Brenda Wonsetler, RT (R), MSM  
Director of Radiology  
City Hospital, Inc.  
WVUH-East

141722

NMSS/RGN1 MATERIALS-002



## Katin Radiation Therapy

**Board Certified in the  
Practice of Radiation Oncology**

- Intensity Modulated Radiation Therapy (IMRT)
- Image Guided Radiation Therapy (IGRT)
- 3-D Conformal Radiotherapy
- Brachytherapy

**Edward W. Kiggundu, M.D.****Medical Degree:**

Jefferson Medical College  
Thomas Jefferson University  
Philadelphia, PA

**Residency:**

Internship Medicine  
Yale School of Medicine

**Radiation Oncology**

Massachusetts General Hospital  
Harvard Medical School

Boston, Massachusetts

**Clinical Fellowship:**

Joint Center of Radiation Oncology  
Harvard Medical School  
Boston, Massachusetts


February 28, 2008

Dr. Dimitri Misailidis,

1. Brachytherapy procedures will be performed only on patients who can be released under the provisions of 10 CFR 35.75. The authorization of patient release will be based on the dose rate at 1 meter. In cases where shielding by tissue is not sufficient to reduce the dose rate below 1 mrem/hr for I-125 or 3 mrem/hr for Pd-103, external shielding materials such as lead apron and shielding under-garments will be used.
2. A copy of the written directives (Brachytherapy Prescription) that will be used for all implants is attached.

Sincerely,

Ayoola Akinradewo, Ph.D., DABR  
21<sup>st</sup> Century Oncology  
Katin Radiation Therapy  
2000 Foundation Way, Ste 1100  
Martinsburg, WV 25401



21st Century Oncology

**TREATMENT PRESCRIPTION**

**BRACHYTHERAPY PRESCRIPTION**

Physician Orders for Brachytherapy Procedures:					
Physics Consult _____ Nutrition Evaluation _____ Conformal _____ CT Scan _____ CT Scan Boost _____ Fusion _____ Verification films _____  Consultation 1            2            3            4            5 <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<b>Treatment Intent:</b> Curative <input type="checkbox"/> Palliative <input type="checkbox"/> Adjuvant <input type="checkbox"/> Local Control <input type="checkbox"/>				
<b>Normal tissue dose limits:</b>					
Site					Gy

Anatomical Site:	Rx Pt	Dose per FX (Gy)	Fx per week	Total		Modality/energy /isotope
				Dose (Gy)	#Fx	

Physician signature: \_\_\_\_\_ Date: \_\_\_\_\_

**Amendments of prescription**

Date	Change	MD Initials	Physicist Initials	Dosimetrist & Date	Notes: